North America
Kyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
Princeton, NJ and TOKYO, April 2, 2024 - Kyowa Kirin Co., Ltd. (TSE: 4151) a Japan-based global specialty pharmaceutical company (J-GSP) creating innovative medical solutions utilizing the latest biotechnology, today announced that pre-clinical data of tivozanib (KHK-4951), an investigational product, assessing the ocular pharmacokinetics of a novel tivozanib eye drop for neovascular age-related macular degeneration (nAMD), will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held in Seattle, Washington from May 5-9, 2024.
Age-related macular degeneration (AMD) is a leading cause of severe vision loss and blindness for people aged 60 years and older in developed countries worldwide, with a profound impact on the quality of life of affected individuals. With the increase in life expectancy, the number of reported cases of AMD is increasing. The disease and its current treatment regimen add s
02 April 2024